BriaCell accelerates Phase 3 enrollment, raises $30M, advances next-gen pipeline

Filed June 9, 2026 · Period ending April 30, 2026 · Compared to 10-Q Jun 16, 2025 · ~1 min read

Key Changes

• high

  Phase 3 trial enrollment accelerated to 160+ patients (from 75 in April 2025), with topline data now on track for H1 2026. Trial momentum supported by extended survival data showing 9 of 25 Phase 2 patients alive 18-47 months post-enrollment.

  MD&A: Phase 3 enrollment and Phase 2 survival verify on EDGAR →
• high

  January 2026 public offering raised ~$30M gross proceeds, improving working capital to $21.8M (from $10.5M in April 2025) and extending runway as R&D spending increased 32% year-over-year to $18.7M for nine months.

  MD&A: Financing and working capital verify on EDGAR →
• high

  FDA cleared Bria-BRES+ IND in May 2026, enabling Phase 1/2a study in metastatic breast cancer. Clinical supplies completed for both Bria-BRES+ and Bria-PROS+ (prostate cancer), with Bria-OVA+ (ovarian cancer) in development.

  MD&A: OTS+ platform expansion verify on EDGAR →